Valeant Pharmaceuticals International Revenue Quarterly YoY Growth:
24.79% for March 31, 2013Valeant Pharmaceuticals International Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 24.79% |
| Dec. 31, 2012 | 43.26% |
| Sept. 30, 2012 | 47.21% |
| June 30, 2012 | 34.58% |
| March 31, 2012 | 51.52% |
| Dec. 31, 2011 | 33.79% |
| Sept. 30, 2011 | 188.4% |
| June 30, 2011 | 155.2% |
| March 31, 2011 | 157.3% |
| Dec. 31, 2010 | 113.5% |
| Sept. 30, 2010 | -2.00% |
| June 30, 2010 | 23.37% |
| March 31, 2010 | 26.72% |
| Dec. 31, 2009 | 32.81% |
| Sept. 30, 2009 | 17.36% |
| June 30, 2009 | 4.00% |
| March 31, 2009 | -16.87% |
| Dec. 31, 2008 | -10.99% |
| Sept. 30, 2008 | -4.13% |
| June 30, 2008 | -8.34% |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
VRX Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Actavis | 24.35% |
| Mylan | 3.02% |
| Warner Chilcott | -5.26% |
VRX Revenue Quarterly YoY Growth Rankings
| Overall |
89th percentile 779 of 7593 |
| Sector |
80th percentile 125 of 650 in Healthcare |
| Industry |
75th percentile 16 of 65 in Drug Manufacturers - Specialty & Generic |
VRX Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -16.87% | Mar 2009 |
| Maximum | 188.4% | Sep 2011 |
| Average | 45.57% |
